In medicine and psychology, emotional lability is a sign or symptom typified by exaggerated changes in mood or affect in quick succession. Sometimes the emotions expressed outwardly are very different from how the person feels on the inside. These strong emotions can be a disproportionate response to something that happened, but other times there might be no trigger at all. The person experiencing emotional lability usually feels like they do not have control over their emotions. For example, someone might cry uncontrollably in response to any strong emotion even if they do not feel sad or unhappy.Emotional lability is seen or reported in various conditions including borderline personality disorder, histrionic personality disorder, post-traumatic stress disorder, hypomanic or manic episodes of bipolar disorder, and neurological disorders or brain injury (where it is termed pseudobulbar affect), such as after a stroke. It has sometimes been found to have been a harbinger, or early warning, of certain forms of thyroid disease. Emotional lability also results from  intoxication with certain substances, such as alcohol and benzodiazepines. It is also an associated feature of ADHD and autism.Children who display a high degree of emotional lability generally have low frustration tolerance and frequent crying spells or tantrums. During preschool, ADHD with emotional lability is associated with increased impairment and may be a sign of internalizing problems or multiple comorbid disorders.
Eliglustat, sold under the brand name Cerdelga, is a medication used for the treatment of Gauchers disease. It was discovered at the University of Michigan, developed by Genzyme Corp, and was approved by the FDA in August 2014. Commonly used as the tartrate salt, the compound is believed to work by inhibition of glucosylceramide synthase. According to an article in Journal of the American Medical Association the oral substrate reduction therapy resulted in "significant improvements in spleen volume, hemoglobin level, liver volume, and platelet count" in untreated adults with Gaucher disease Type 1. History
Norman Radin began exploring the possibility of inhibiting the synthesis of lipid substrates involved in Gauchers disease as early as 1982, and, in collaboration with the laboratory of Jim Shayman, found several candidate inhibitors in the mid-1990s. Genzyme initially rejected the candidates developed by Radin and Shayman, but after a news broke of a competitor developing a new treatment for Gauchers disease, licensed the Radin/Shayman patents in 2000. Eliglustat did not receive FDA approval for another 14 years, a delay that Shayman speculated was due to some company leaders not being fully committed to developing a drug that would compete with imiglucerase (brand name Cerezyme), Genzymes flagship treatment for Gauchers disease. Society and culture
Economics
In 2014, the annual cost of eliglustat taken orally twice a day was $310,250. Cerezyme cost about $300,000 for the intravenous medication if taken twice a month. Manufacturing costs for eliglustat are slightly lower than for imiglucerase.